{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:01:14Z","timestamp":1790402474638,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1245\/s10434-018-07143-4","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T22:27:14Z","timestamp":1546986434000},"page":"1055-1062","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma"],"prefix":"10.1245","volume":"26","author":[{"given":"Valerio","family":"Belgrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Pettersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas A.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Katsarelias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Olofsson Bagge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,7]]},"reference":[{"key":"7143_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.det.2012.04.001","volume":"30","author":"EG Little","year":"2012","unstructured":"Little EG, Eide MJ. Update on the current state of melanoma incidence. Dermatol Clin. 2012;30:355\u201361.","journal-title":"Dermatol Clin."},{"key":"7143_CR2","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jid.2016.01.035","volume":"136","author":"DC Whiteman","year":"2016","unstructured":"Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol. 2016;136:1161\u201371.","journal-title":"J Invest Dermatol."},{"key":"7143_CR3","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1245\/ASO.2005.05.025","volume":"12","author":"TM Pawlik","year":"2005","unstructured":"Pawlik TM, Ross MI, Johnson MM, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Onco. 2005;12:587\u201396.","journal-title":"Ann Surg Onco."},{"key":"7143_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ctrv.2016.02.007","volume":"45","author":"S Sloot","year":"2016","unstructured":"Sloot S, Speijers MJ, Bastiaannet E, Hoekstra HJ. Is there a relation between type of primary melanoma treatment and the development of intralymphatic metastasis? A review of the literature. Cancer Treat Rev. 2016;45:120\u20138.","journal-title":"Cancer Treat Rev."},{"key":"7143_CR5","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1245\/s10434-011-2196-z","volume":"19","author":"R Olofsson","year":"2012","unstructured":"Olofsson R, Bergh P, Berlin O, et al. Long-term outcome of isolated limb perfusion in advanced soft tissue sarcoma of the extremity. Ann Surg Oncol. 2012;19:1800\u20137.","journal-title":"Ann Surg Oncol."},{"key":"7143_CR6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/02656736.2016.1188999","volume":"32","author":"V Belgrano","year":"2016","unstructured":"Belgrano V, Ben-Shabat I, Bergh P, Olofsson Bagge R. Isolated limb perfusion as a treatment option for rare types of tumours. Int J Hyperthermia. 2016;32:595\u20139.","journal-title":"Int J Hyperthermia."},{"key":"7143_CR7","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.ejso.2016.10.005","volume":"43","author":"A Testori","year":"2017","unstructured":"Testori A, Ribero S, Bataille V. Diagnosis and treatment of in-transit melanoma metastases. Eur J Surg Oncol. 2017;43:544\u201360.","journal-title":"Eur J Surg Oncol."},{"key":"7143_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2217\/imt.15.35","volume":"7","author":"DB Johnson","year":"2015","unstructured":"Johnson DB, Puzanov I, Kelley MC. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy. 2015;7:611\u20139.","journal-title":"Immunotherapy."},{"key":"7143_CR9","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1245\/s10434-014-4169-5","volume":"22","author":"JF Thompson","year":"2015","unstructured":"Thompson JF, Agarwala SS, Smithers BM, et al. Phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Ann Surg Oncol. 2015;22:2135\u201342.","journal-title":"Ann Surg Oncol."},{"key":"7143_CR10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/00000658-195810000-00009","volume":"148","author":"O Creech Jr","year":"1958","unstructured":"Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616\u201332.","journal-title":"Ann Surg."},{"key":"7143_CR11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1634\/theoncologist.2009-0325","volume":"15","author":"D Moreno-Ramirez","year":"2010","unstructured":"Moreno-Ramirez D, de la Cruz-Merino L, Ferrandiz L, Villegas-Portero R, Nieto-Garcia A. Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist. 2010;15:416\u201327.","journal-title":"Oncologist."},{"key":"7143_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/CMR.0000000000000177","volume":"25","author":"JP Deroose","year":"2015","unstructured":"Deroose JP, Gr\u00fcnhagen DJ, Eggermont AM, Verhoef C. Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases. Melanoma Res. 2015;25:427\u201331.","journal-title":"Melanoma Res."},{"key":"7143_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1245\/ASO.2005.03.060","volume":"12","author":"DJ Gr\u00fcnhagen","year":"2005","unstructured":"Gr\u00fcnhagen DJ, van Etten B, Brunstein F, et al. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol. 2005;12:609\u201315.","journal-title":"Ann Surg Oncol."},{"key":"7143_CR14","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ejso.2005.10.009","volume":"32","author":"EM Noorda","year":"2006","unstructured":"Noorda EM, Vrouenraets BC, Nieweg OE, van Geel AN, Eggermont AM, Kroon BB. Repeat isolated limb perfusion with TNF alpha and melphalan for recurrent limb melanoma after failure of previous perfusion. Eur J Surg Oncol. 2006;32:318\u201324.","journal-title":"Eur J Surg Oncol."},{"key":"7143_CR15","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1245\/s10434-018-6459-9","volume":"25","author":"D Katsarelias","year":"2018","unstructured":"Katsarelias D, Radbo E, Ben-Shabat I, Mattsson J, Olofsson Bagge R. The effect of temperature and perfusion time on response, toxicity, and survival in patients with in-transit melanoma metastases treated with isolated limb perfusion. Ann Surg Oncol. 2018;25:1836\u201342.","journal-title":"Ann Surg Oncol."},{"key":"7143_CR16","volume-title":"WHO handbook for reporting results of cancer treatment","author":"World Health Organization","year":"1979","unstructured":"World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979."},{"key":"7143_CR17","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/0277-5379(82)90235-8","volume":"18","author":"J Wieberdink","year":"1982","unstructured":"Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905\u201310.","journal-title":"Eur J Cancer Clin Oncol."},{"key":"7143_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313.","journal-title":"Ann Surg."},{"key":"7143_CR19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3109\/02656736.2013.802374","volume":"29","author":"R Olofsson","year":"2013","unstructured":"Olofsson R, Mattsson J, Lindner P. Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma. Int J Hyperthermia. 2013;29:551\u20137.","journal-title":"Int J Hyperthermia."},{"key":"7143_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3109\/02656736.2014.931601","volume":"30","author":"R Olofsson Bagge","year":"2014","unstructured":"Olofsson Bagge R, Mattsson J, Hafstrom L. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities: long-term follow-up of a randomised trial. Int J Hyperthermia. 2014;30:295\u20138.","journal-title":"Int J Hyperthermia."},{"key":"7143_CR21","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1200\/JCO.2005.05.5152","volume":"24","author":"WR Cornett","year":"2006","unstructured":"Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol. 2006;24:4196\u2013201.","journal-title":"J Clin Oncol."},{"key":"7143_CR22","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1200\/JCO.2006.09.8459","volume":"25","author":"FJ Lejeune","year":"2007","unstructured":"Lejeune FJ, Eggermont AM. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs. J Clin Oncol. 2007;25:1449\u201350. (author reply 1450\u20131441)","journal-title":"J Clin Oncol."},{"key":"7143_CR23","doi-asserted-by":"publisher","first-page":"5398","DOI":"10.1158\/0008-5472.CAN-15-1184","volume":"75","author":"A Martner","year":"2015","unstructured":"Martner A, Johansson J, Ben-Shabat I, Bagge RO. Melphalan, antimelanoma immunity, and inflammation: letter. Cancer Res. 2015;75:5398\u20139.","journal-title":"Cancer Res."},{"key":"7143_CR24","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1158\/0008-5472.CAN-14-2089","volume":"75","author":"AM Dudek-Peric","year":"2015","unstructured":"Dudek-Peric AM, Ferreira GB, Muchowicz A, et al. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. Cancer Res. 2015;75:1603\u201314.","journal-title":"Cancer Res."},{"key":"7143_CR25","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1245\/s10434-016-5150-2","volume":"23","author":"LA Dossett","year":"2016","unstructured":"Dossett LA, Ben-Shabat I, Olofsson Bagge R, Zager JS. Clinical response and regional toxicity following isolated limb infusion compared with isolated limb perfusion for in-transit melanoma. Ann Surg Oncol. 2016;23:2330\u20135.","journal-title":"Ann Surg Oncol."},{"key":"7143_CR26","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1245\/s10434-011-2151-z","volume":"19","author":"CY Chai","year":"2012","unstructured":"Chai CY, Deneve JL, Beasley GM, et al. A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Ann Surg Oncol. 2012;19:1637\u201343.","journal-title":"Ann Surg Oncol."},{"key":"7143_CR27","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1080\/14712598.2016.1233961","volume":"16","author":"C Luu","year":"2016","unstructured":"Luu C, Khushalani NI, Zager JS. Intralesional and systemic immunotherapy for metastatic melanoma. Expert Opin Biol Ther. 2016;16:1491\u20139.","journal-title":"Expert Opin Biol Ther."},{"key":"7143_CR28","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780\u20138.","journal-title":"J Clin Oncol."},{"key":"7143_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30\u20139.","journal-title":"N Engl J Med."},{"key":"7143_CR30","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","volume":"36","author":"J Larkin","year":"2018","unstructured":"Larkin J, Minor D, D\u2019Angelo S, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol. 2018;36:383\u201390.","journal-title":"J Clin Oncol."},{"key":"7143_CR31","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390:1853\u201362.","journal-title":"Lancet."},{"key":"7143_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/2326-6066.CIR-17-0356","volume":"6","author":"CE Ariyan","year":"2018","unstructured":"Ariyan CE, Brady MS, Siegelbaum RH, et al. Robust antitumor responses result from local chemotherapy and CTLA-4 blockade. Cancer Immunol Res. 2018;6:189\u2013200.","journal-title":"Cancer Immunol Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-018-07143-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-018-07143-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-018-07143-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:05:41Z","timestamp":1578355541000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-018-07143-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,7]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["7143"],"URL":"https:\/\/doi.org\/10.1245\/s10434-018-07143-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,7]]},"assertion":[{"value":"19 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}